Autolus Limited Sustainability Profile
Autolus Limited, a pioneering biotechnology company headquartered in Great Britain, focuses on developing innovative T-cell therapies for cancer treatment. Founded in 2014, Autolus has rapidly established itself in the cell and gene therapy industry, with significant operational presence in Europe and North America. The company is renowned for its proprietary technology platform, which enables the creation of next-generation CAR T-cell therapies. These therapies are designed to enhance the efficacy and safety of cancer treatments, setting Autolus apart in a competitive market. Notable achievements include successful clinical trials and partnerships that underscore its commitment to advancing cancer care. With a strong market position, Autolus Limited continues to lead the way in transforming the landscape of oncology, striving to provide patients with more effective and personalised treatment options.
DitchCarbon Score
How does Autolus Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Autolus Limited's score of 23 is lower than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Autolus Limited's reported carbon emissions
Autolus Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Autolus Therapeutics plc, which may influence its climate commitments and reporting practices. Despite the lack of direct emissions data, Autolus Limited is part of a corporate family that may have broader sustainability initiatives. However, no specific reduction targets or climate pledges have been documented for Autolus Limited itself. The absence of data suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. As a current subsidiary, Autolus Limited's climate commitments may align with those of its parent company, Autolus Therapeutics plc, but specific details on emissions reduction initiatives or targets are not available. The company is encouraged to establish clear climate goals and report on its emissions to enhance transparency and accountability in its environmental impact.
How Carbon Intensive is Autolus Limited's Industry?
How Carbon Intensive is Autolus Limited's Location?
Autolus Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Autolus Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
